Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MaxCyte Inc (MXCT)
NASDAQ:MXCT
MaxCyte (MXCT) Stock Price & Analysis
50 Followers
MXCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.45 - $5.55
Previous Close$3.88
Volume22.36K
Average Volume (3M)590.73K
Market Cap
$405.58M
Enterprise Value$254.47M
Total Cash (Recent Filing)$168.29M
Total Debt (Recent Filing)$18.74M
Price to Earnings (P/E)-10.6
Beta1.71
Next Earnings
May 07, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding103,504,571
10 Day Avg. Volume427,630
30 Day Avg. Volume590,728
Standard Deviation0.17
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.34
Price to Sales (P/S)46.18
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.16
Enterprise Value/Gross Profit6.96
Enterprise Value/Ebitda-6.29
Forecast
1Y Price Target
$8.18Price Target Upside110.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
MaxCyte News
Ownership Overview
10.56% Insiders
19.68% Mutual Funds
9.63% Other Institutional Investors
60.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MXCT FAQ
What was MaxCyte Inc’s price range in the past 12 months?
MaxCyte Inc lowest stock price was $2.45 and its highest was $5.54 in the past 12 months.
What is MaxCyte Inc’s market cap?
Currently, no data Available
When is MaxCyte Inc’s upcoming earnings report date?
MaxCyte Inc’s upcoming earnings report date is May 07, 2024 which is in 9 days.
How were MaxCyte Inc’s earnings last quarter?
MaxCyte Inc released its earnings results on Mar 12, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.018.
Is MaxCyte Inc overvalued?
According to Wall Street analysts MaxCyte Inc’s price is currently Undervalued.
Does MaxCyte Inc pay dividends?
MaxCyte Inc does not currently pay dividends.
What is MaxCyte Inc’s EPS estimate?
MaxCyte Inc’s EPS estimate is -$0.13.
How many shares outstanding does MaxCyte Inc have?
MaxCyte Inc has 104,128,650 shares outstanding.
What happened to MaxCyte Inc’s price movement after its last earnings report?
MaxCyte Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 4.523%.
Which hedge fund is a major shareholder of MaxCyte Inc?
Currently, no hedge funds are holding shares in MXCT
---
MaxCyte Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.18 (110.00% Upside)
$8.18 (110.00% Upside)
Blogger Sentiment
Bullish
MXCT Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.51%
12-Months-Change
Fundamentals
Return on Equity
-15.51%
Trailing 12-Months
Asset Growth
-11.69%
Trailing 12-Months
Company Description
MaxCyte Inc
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
---
MXCT Stock 12 Months Forecast
Average Price Target
$8.18
▲(110.00% Upside)
Technical Analysis
Allergy Therapeutics
―
Avacta Group plc
―
BioLife Solutions
―
MaxCyte
―
RUA Life Sciences
―
Best Analysts Covering MXCT
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-11.71%
reiterated a buy rating 2 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.71% per trade.
---